Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Targeted Medical Education | OTHER |
Not provided
Not provided
Not provided
Not provided
The JuLi Registry seeks to fill some of the gaps associated with the clinical use of CBD (cannabidiol) and other cannabinoid formulations including THC and others. The overarching goal of this Registry is to rapidly advance research and understanding of the use of cannabis and hemp-based formulations, in the clinical community setting, when it is utilized to manage the symptoms of cancer treatment and other underlying health issues. These symptoms include nausea, neuropathy, and sleeplessness and chronic pain.
The JuLi Registry seeks to fill some of the gaps associated with the clinical application of CBD (cannabidiol) and other cannabinoid formulations including THC and others. It will also serve as a platform for discovery, whereby observations of patient symptoms, specific cannabis formulations, delivery methods and clinical outcomes, become the source of more in-depth research projects.
The JuLi Registry is a prospective observational Registry documenting utility and patient experience for patients seeking to use therapeutic cannabis and hemp-based products as a means of symptom relief and management related to various diseases.
Targeted symptoms and conditions include:
Data to be recorded includes:
The purpose of this Registry is to provide a platform for physicians and patients to collaborate on hemp and cannabis research and advance the understanding of the application of cannabinoids for symptom relief associated with various medical conditions.
Patients greater than or equal to 21 years of age seeking to use CBD or other cannabis-based formulations, where legal, will be invited to participate.
Data collected in the normal course of a patient's visit and follow up are entered. This is an observational study; no specific patient interventions are required. Patients must have requested a cannabis-based medicament from their provider. Or be otherwise deemed eligible per the research protocol and choose to participate in a self-directed manner.
Data will be collected at various time points, including:
All patients must sign an electronic informed consent form prior to their prospective data being entered into the Registry.
All demographic, diagnostic, hemp/cannabis formulation and follow up data will be entered by patients. Consented patients will record compliance with recommendations, usage and symptom relief. They will be asked to take symptom specific surveys.
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Symptom Relief | Percentage of patients who obtain and report symptom relief, by symptom, condition and cannabis formulation | 3 months |
| Reduction in reliance on Rx medications | Percentage of patients who report reduction or increase in use of Rx medications | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Reduction in reliance on OTC medications | Percentage of patients who report reduction or increase in use of Rx medications | 3 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
All patients greater than or equal to 21 years of age who are seeking to use hemp-based or cannabis-based formulations to relieve symptoms associated with medical interventions or conditions
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Mary Kay K Hardwick, MBA | Contact | 5106826256 | mkhardwick@tmebcn.com | |
| Peter Beitsch, MD | Contact | 214 350 6672 | pbeitsch@tmebcn.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Precision Cancer Specialists | Recruiting | Los Gatos | California | 95032 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 29533978 | Background | Zou S, Kumar U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int J Mol Sci. 2018 Mar 13;19(3):833. doi: 10.3390/ijms19030833. | |
| 28686542 | Result | Freitas HR, Isaac AR, Malcher-Lopes R, Diaz BL, Trevenzoli IH, De Melo Reis RA. Polyunsaturated fatty acids and endocannabinoids in health and disease. Nutr Neurosci. 2018 Dec;21(10):695-714. doi: 10.1080/1028415X.2017.1347373. Epub 2017 Jul 7. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D059350 | Chronic Pain |
| D001068 | Feeding and Eating Disorders |
| D001008 | Anxiety Disorders |
| D020447 | Parasomnias |
| D009325 | Nausea |
| ID | Term |
|---|---|
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
| Justin Lo MD | Recruiting | San Jose | California | 95128 | United States |
|
| Nashville Breast Center | Recruiting | Nashville | Tennessee | 37203 | United States |
|
| Dallas Surgical Group | Recruiting | Dallas | Texas | 75231 | United States |
|
| D012817 | Signs and Symptoms, Digestive |
| D001523 | Mental Disorders |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |